| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $31,147,928 ) (Continued on the next page) |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R00EY032181 | Epigenomic mechanisms regulating RGC survival and axon regeneration | 000 | 5 | NIH | 1/16/2025 | $249,998 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK137983 | CYP4F Enzymes Regulate N-Acyl Amino Acid Signaling in Humans | 000 | 1 | NIH | 12/23/2024 | $665,717 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA262629 | Personalized Adoptive T-cell Therapy for AML | 000 | 4 | NIH | 12/23/2024 | $655,651 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01MH116170 | Cerebellar Modulation of Cognition in Psychosis | 000 | 7 | NIH | 12/6/2024 | $693,159 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG051658 | AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline | 001 | 7 | NIH | 11/26/2024 | $763,807 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA276107 | Control of cancer cachexia via stimulation of resolution of inflammation | 000 | 2 | NIH | 11/25/2024 | $622,526 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG079864 | Brain Vulnerability in Delirium and Alzheimer’s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 000 | 3 | NIH | 11/26/2024 | $746,750 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL177355 | Targeted Gene Therapies for the Prevention of Prosthetic Bypass Graft Failure | 000 | 1 | NIH | 12/26/2024 | $786,188 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23HL171855 | Mixed meal tolerance test elicited metabolite responses as novel markers of cardiometabolic risk | 000 | 2 | NIH | 1/28/2025 | $190,670 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01CA263986 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients | 000 | 4 | NIH | 1/20/2025 | $220,834 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258372 | Role of extracellular matrix proteins and tumor stroma in DNA repair and cancer progression | 000 | 5 | NIH | 1/27/2025 | $360,281 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS133187 | Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease | 000 | 2 | NIH | 1/27/2025 | $590,222 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NR019628 | Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention | 000 | 5 | NIH | 12/16/2024 | $461,935 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL171101 | Rechargeable Anti-thrombogenic Films for Blood Contacting Applications | 000 | 2 | NIH | 12/17/2024 | $652,429 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AR062173 | The IL-23/IL-17 Axis in Inflammatory Arthritis | 000 | 10 | NIH | 11/27/2024 | $543,762 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258776 | Pan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasion | 000 | 4 | NIH | 1/22/2025 | $529,555 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK130929 | Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) | 000 | 4 | NIH | 11/27/2024 | $342,342 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P30HS029762 | Massachusetts Institute for Equity-Focused Learning Health System Science (MIELHSS) | 000 | 2 | AHRQ | 11/18/2024 | $997,446 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA257672 | Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy | 000 | 3 | NIH | 12/18/2024 | $638,478 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL171121 | Novel Role Of ACTN4 in Sodium Reabsorption and Salt-Sensitive Hypertension | 000 | 2 | NIH | 11/20/2024 | $631,041 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL157991 | Mapping & quantifying lymphatic drainage of the arm's alternate pathway | 000 | 5 | NIH | 12/10/2024 | $434,000 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23HL177335 | Plasma protein markers of the blood pressure response during exercise and their relation to incident hypertension and cardiovascular disease | 000 | 1 | NIH | 12/18/2024 | $190,491 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL129506 | Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells | 000 | 10 | NIH | 11/19/2024 | $696,709 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS126282 | Prospective Validation of Neurophysiologic Outcome Prediction in Acute Brain Injury | 000 | 3 | NIH | 12/9/2024 | $663,875 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK125283 | Mitochondrial BCAA transporter in physiology and disease | 000 | 4 | NIH | 12/9/2024 | $425,185 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K99NS140561 | Identification of a Circuit Basis for Neuropathic Pain in the Parabrachial Nucleus | 000 | 1 | NIH | 11/20/2024 | $124,713 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R00CA259329 | Elucidating a Novel Mechanism for LATS1/2 in Suppressing Tumorigenesis | 000 | 5 | NIH | 2/13/2025 | $224,101 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23AG068364 | Understanding the structural, functional, and prognostic implications of cortical excitability in Alzheimer's disease | 000 | 4 | NIH | 12/30/2024 | $75,352 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258442 | Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma | 000 | 4 | NIH | 12/12/2024 | $382,146 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA285395 | Resolution of inflammation in chemical-induced cancer | 000 | 1 | NIH | 12/27/2024 | $749,474 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL177076 | Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR | 000 | 1 | NIH | 2/24/2025 | $777,258 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK128406 | The role of interferon regulatory factors in tanycytes during HFD-induced inflammation, obesity and glucose dysregulation | 000 | 4 | NIH | 4/11/2025 | $547,478 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NR019628 | Biochemical profiling to identify cardiometabolic responsiveness to an endurance exercise intervention | 001 | 5 | NIH | 4/11/2025 | $51,327 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL133870 | Proteomics of Cardiometabolic and Renal Traits in African Americans | 000 | 7 | NIH | 3/26/2025 | $445,110 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK139288 | Mitochondrial DAMPs-driven Mechanisms of Liver Fibrosis in NASH | 000 | 2 | NIH | 4/4/2025 | $614,322 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01CA236489 | Developing a Translation Pipeline for VHL Mutant Malignancies | 002 | 6 | NIH | 4/4/2025 | $545,600 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK135672 | Cav1.2 in bladder physiology and pathology | 000 | 2 | NIH | 3/27/2025 | $486,870 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG082093 | Non-coding RNAs in resilience to Alzheimer’s Disease | 000 | 3 | NIH | 3/6/2025 | $759,851 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K01DK139434 | Targeted mRNA Delivery to Improve Diabetic Wound Healing | 000 | 2 | NIH | 4/10/2025 | $150,736 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23ES035863 | Climate Variability and Respiratory Health in Asthma and COPD | 001 | 2 | NIH | 4/9/2025 | $0 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23AT011043 | Understanding components of mind-body exercise for physical activity engagement in metabolic syndrome | 000 | 5 | NIH | 3/13/2025 | $163,109 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG072899 | Inflammasome activation in modulation of Alzheimer’s Disease by alcohol Administrative Supplement | 000 | 5 | NIH | 3/14/2025 | $192,849 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K24AT009465 | Mentoring and Patient-Oriented Research in Integrative Medicine | 001 | 7 | NIH | 3/14/2025 | $140,162 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23ES035863 | Climate Variability and Respiratory Health in Asthma and COPD | 000 | 2 | NIH | 3/17/2025 | $256,202 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R00DC020185 | Using High Definition transcranial Direct Current Stimulation Guided by Electrophysiology and Diffusion Tensor Imaging to Treat Verbal Retrieval Deficits Secondary to Chronic Traumatic Brain Injury | 000 | 3 | NIH | 4/1/2025 | $248,947 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA271601 | Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments. | 000 | 3 | NIH | 4/1/2025 | $583,542 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK136699 | Use of Modified mRNA for the Treatment of Diabetic Foot Ulceration | 000 | 2 | NIH | 4/1/2025 | $661,095 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AG085089 | A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer’s disease | 000 | 2 | NIH | 4/1/2025 | $194,513 |
| | 2025 | 2025 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08DK132413 | Lymphatic-adipocyte interactions in obesity and lymphedema | 000 | 4 | NIH | 3/31/2025 | $164,484 |
|
